Jun 13, 2021 Portfolio Update: What's Ahead for Our "Other" Vaccine Stock The portfolio continues to do well, with one exception - our "second vaccine stock" CureVac (CVAC). This post is for paying subscribers only Subscribe now Already have an account? Sign in
